Navigation Links
Novo Nordisk Addresses Innovation in Diabetes Care in Second Issue of Industry Resource for Information on Diabetes and Chronic Disease
Date:7/12/2010

PRINCETON, N.J., July 12 /PRNewswire/ -- Novo Nordisk Inc., a global healthcare company and leader in diabetes care, today announced the second issue of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.

The second issue of the Novo Nordisk BlueSheet examines how insulin has evolved over the last 90 years, how it is developed today, the use of insulin devices in the U.S., and the outlook for next generation insulins. Each quarter, the Novo Nordisk BlueSheet will highlight key issues in diabetes prevention, detection, treatment and care, as well as related topics from the legislative process to public education.

To read the Novo Nordisk BlueSheet, go to: http://press.novonordisk-us.com/bluesheet.

"Innovation and scientific research and discovery are our most powerful tools in defeating diabetes with better methods of disease prevention, detection, treatment, and care," said Jerzy Gruhn, president of Novo Nordisk Inc. "At Novo Nordisk, we are committed to building an environment that supports the discovery of new products and solutions that can significantly impact the millions of people living with diabetes."

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 87 years of innovation and leadership in diabetes care.  The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success.  Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries.  Novo Nordisk's B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp
2. Novo Nordisk Awards More Than $300,000 in Grants to Support Education and Community Health Programs
3. Novo Nordisk partners with international scientific community for Victoza(R) cardiovascular outcomes trial
4. Novo Nordisk Awarded Department of Veterans Affairs National Insulin Contract
5. Novo Nordisks Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
6. Novo Nordisk is Changing Possibilities in Hemophilia
7. Novo Nordisk Wins Design Award for NovoTwist(TM) Needle
8. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
9. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
10. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
11. Baxa Addresses Health-System Capital Shortage With New Programs for IntelliFlowRx(TM) and IntelliFill i.v.(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... CITY, Calif., Feb. 8, 2016  Aoxing Pharmaceutical Company, Inc. (NYSE ... fiscal year 2016, ended December 31, 2015, the Company achieved ... recorded in the same quarter in fiscal 2015. ... in Q2 of fiscal year 2016 was $2,068,635, or $.03 ... or $.01 per share, in the Q2 of fiscal year ...
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
(Date:2/8/2016)...  HemaFlo Therapeutics, Inc. announced today that the United States ... 9,119,880 covering the use of NephroFlow to treat acute kidney ... founder, said, "We are pleased to secure our rights to ... , PhD, HemaFlo,s founder, said, "We are pleased to secure ... Dale Peterson , PhD, HemaFlo,s founder, said, "We ...
Breaking Medicine Technology:
(Date:2/8/2016)... , ... February 08, 2016 , ... Discover the Rocky ... over 1,400 booths and 700 companies. Attendees also get to see the most ... Colorado Garden & Home Show , at the Colorado Convention Center - 700 14th ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua Rosenthal, ... how healthcare companies can use newly released government data on populations and physicians ... and intervene and capture the value they create to succeed in new economic ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , ... with an estimated 5000 perioperative nurses in attendance to study the latest ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... eating disorder treatment helps to reduce the frequency and level of relapse. ... Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the ...
Breaking Medicine News(10 mins):